公开(公告)号：US20220185902A1

公开(公告)日：2022-06-16

申请号：US17538530

申请日：2021-11-30

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy POULTON ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget A. Cooksey ,  Vanya Pande ,  Adam W. Clarke

IPC: C07K16/28 ,  A61P11/06 ,  C07K16/24

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

公开(公告)号：US11220549B2

公开(公告)日：2022-01-11

申请号：US16164509

申请日：2018-10-18

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy Poulton ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget A. Cooksey ,  Vanya Pande ,  Adam W. Clarke

IPC: C07K16/28 ,  A61P11/06 ,  C07K16/24 ,  A61P37/06 ,  A61K39/00

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.